Stockreport

Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy

Atara Biotherapeutics, Inc.  (ATRA) 
Last atara biotherapeutics, inc. earnings: 2/27 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: investors.atarabio.com/investor-relations
PDF Second IND Clearance for ATA3219 Following Non-Hodgkin’s Lymphoma (NHL) and First in an Autoimmune Disease IndicationInitial Clinical Data in NHL Anticipated in H2 2024 [Read more]